Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behcet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial

发表于 6 天前

期刊：Annals of the Rheumatic Diseases

文献作者：Rosaria Talarico; Nazzareno Italiano; Giacomo Emmi; Matteo Piga; Luca Cantarini; Irene Mattioli; Alberto Floris; Stefano Gentileschi; Federica Di Cianni; Maria Letizia Urban; Emanuele Chiara; Diana Marinello; Alessandra Del Bianco; Michele Figus; Chiara Posarelli; Claudia Fabiani; Sabrina Vagnani; Gianni Andreozzi; Valentina Lorenzoni; Giuseppe Turchetti; Alberto Cauli; Lorenzo Emmi; Carlo Salvarani; Ornella Della Casa Alberighi; Stefano Bombardieri; Marta Mosca

出版日期：2025-3-

DOI号：10.1136/ard-2024-226113

下载链接：https://www.sciencedirect.com/sc ... 003496724005739/pdf

文献链接：https://doi.org/10.1136/ard-2024-226113

当前文献来源于 Elsevier BV。

备注信息：

发表于 6 天前

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[BMJ] Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behcet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[BMJ] Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behcet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial 一键复制